Carbamylation/citrullination of IgG Fc in bronchiectasis, established RA with bronchiectasis and RA smokers: a potential risk factor for disease

David Hutchinson, Alexander Clarke, Kate Heesom, Daniel Murphy, Paul Eggleton

Source: ERJ Open Res, 3 (3) 00018-2017; 10.1183/23120541.00018-2017
Journal Issue: July

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
David Hutchinson, Alexander Clarke, Kate Heesom, Daniel Murphy, Paul Eggleton. Carbamylation/citrullination of IgG Fc in bronchiectasis, established RA with bronchiectasis and RA smokers: a potential risk factor for disease. ERJ Open Res, 3 (3) 00018-2017; 10.1183/23120541.00018-2017

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Antinuclear antibodies and rheumatoid factor are associated with blood eosinophils in asthma and COPD
Source: International Congress 2016 – Immune responses in the lung
Year: 2016


RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients
Source: Eur Respir J 2014; 44: 1082-1085
Year: 2014


Are smoking and COPD associated with ILD onset in rheumatoid arthritis?
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020


The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Increased bronchial hyperreactivity (BHR) in sarcoidosis patients maybe a risk factor for progression of the disease
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009


Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019


IgG immunoglobulin levels and the frequency of respiratory infections in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 543s
Year: 2002

IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007

Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

Smoke exposure as a determinant of autoantibody titre in alpha 1-antitrypsin deficiency and COPD
Source: Eur Respir J 2011; 37: 32-38
Year: 2011



Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project
Source: Eur Respir J 2012; 39: 1343-1353
Year: 2012



Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013



Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013


Hyaluronic acid as a novel systemic biomarker to predict progression and severity in chronic obstructive pulmonary disease
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016

Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Year: 2021



The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories
Source: Eur Respir J, 58 (5) 2004656; 10.1183/13993003.04656-2020
Year: 2021



Is high level of IgE an additional problem in smoking patients with severe and very severe chronic obstructive pulmonary disease (COPD)?
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012

Occupational risk factors and idiopathic pulmonary fibrosis. A case-control study
Source: Annual Congress 2007 - The air we breathe at home and at work
Year: 2007


Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome
Source: Eur Respir J 2011; 37: 1411-1417
Year: 2011